Dare Bioscience, Inc. current report, 05 February 2020

Dare Bioscience, Inc. - Form 8-K Summary

Business Context and Reporting Period

This Current Report on Form 8-K was filed by Dare Bioscience, Inc. (DARE) on February 6, 2020, covering events occurring on February 5, 2020. The company is incorporated in Delaware and its common stock trades on The Nasdaq Capital Market.

Key Financial Metrics

This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The report focuses exclusively on regulatory compliance status.

Material Changes

The primary event reported is the resolution of a listing compliance issue. Dare Bioscience was notified by the Nasdaq Office of General Counsel that it has cured its previously reported non-compliance with Nasdaq Listing Rule 5550(b). Consequently, the company is now in compliance with all applicable listing standards, and a previously scheduled hearing before the Nasdaq Hearings Panel was canceled.

Guidance, Outlook, and Risks

The filing contains no forward-looking guidance, management commentary on financial outlook, or discussion of new risks or contingencies beyond the resolution of the listing status. A press release issued on February 6, 2020, regarding this event is attached as Exhibit 99.1.

Investor Verification Checklist

  • Verify the specific nature of the prior non-compliance with Nasdaq Listing Rule 5550(b) by reviewing previous 8-K filings or Nasdaq correspondence.
  • Confirm the current stock trading status on The Nasdaq Capital Market to ensure no trading halts remain in effect.
  • Review the attached press release (Exhibit 99.1) for any additional details on the cure mechanism.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.